Adoptive immunotherapy using autologous lymphocytes sensitized with HLA class I-matched allogeneic tumor cells

Oncology Reports

Volumn 16, Issue 1, 2006, Pages 165-169

  Yamaguchi, Yoshiyuki ^a   Ohshita, Akiko ^a   Hironaka, Katsuji ^a   Okita, Riki ^a   Okawaki, Makoto ^a   Matsuura, Kazuo ^a   Nagamine, Ichiro ^a   Ikeda, Takuhiro ^a   Ohara, Masahiro ^a   Hihara, Jun ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

Author keywords

Adoptive immunotherapy; In vitro sensitization; Shared antigen; T cell receptor

Indexed keywords

CD3 ANTIGEN; HLA ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; ALLOTRANSPLANTATION; ARTICLE; BIOSYNTHESIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL STRAIN K 562; CELL TRANSPLANTATION; CHEMISTRY; CYTOLOGY; FEMALE; FLOW CYTOMETRY; HUMAN; LYMPHOCYTE; METABOLISM; METHODOLOGY; MONONUCLEAR CELL; NEOPLASM; TUMOR CELL LINE;

ANTIGENS, CD3; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CELL TRANSPLANTATION; FEMALE; FLOW CYTOMETRY; HLA ANTIGENS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; K562 CELLS; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTES; NEOPLASMS; TRANSPLANTATION, HOMOLOGOUS;

EID: 33750736296     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.16.1.165     Document Type: Article

References (26)

1. Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E and Vetto JT: Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 313: 1485-1492, 1985. (Pubitemid 16212345)
2. Rosenberg SA, Spiess P and Lafreniere R: A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233: 1318-1321, 1986. (Pubitemid 16002234)
3. Yamaguchi Y, Ohta K, Shimizu K, Minami K, Noma K, Hihara J and Toge T: Generation of cytotoxic effector lymphocytes by MLTC using tumor cells genetically modified to secrete interleukin-2. Anticancer Res 21: 669-677, 2001. (Pubitemid 32267591)
4. Kimura H and Yamaguchi Y: A phase III randomized study of interleukin-2 lymphokine-activated killer cell immunotherapy combined with chemotherapy or radiotherapy after curative or noncurative resection of primary lung carcinoma. Cancer 80: 42-49, 1997. (Pubitemid 27270918)
5. Takayama T, Sekine T, Makuuchi M, Yamasaki S, Kosuge T, Yamamoto J, Shimada K, Sakamoto M, Hirohashi S, Ohashi Y and Kakizoe T: Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet 356: 802-807, 2000.
6. Merogi AJ, Marrogi AJ, Ramesh R, Robinson WR, Fermin CD and Freeman SM: Tumor-host interaction: analysis of cytokines, growth factors, and tumor-infiltrating lymphocytes in ovarian carcinomas. Hum Pathol 28: 321-331, 1997. (Pubitemid 27106085)
7. Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, Royal RE, Kammula U, White DE, Mavroukakis SA, Rogers LJ, Gracia GJ, Jones SA, Mangiameli DP, Pelletier MM, Gea-Banacloche J, Robinson MR, Berman DM, Filie AC, Abati A and Rosenberg SA: Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 23: 2346-2357, 2005. (Pubitemid 46218728)
8. Yamaguchi Y, Ohta K, Kawabuchi Y, Ohshita A, Okita R, Okawaki M, Hironaka K, Matsuura K and Toge T: Feasibility study of adoptive immunotherapy for metastatic lung tumors using peptide-pulsed dendritic cell-activated killer (PDAK) cells. Anticancer Res 25: 2407-2415, 2005. (Pubitemid 41044723)
9. Chen Y, Wu K, Guo C, Liu C, Han S, Lin T, Ning X, Shi R, Shi Y and Fan D: A novel DNA vaccine containing four mimicry epitopes for gastric cancer. Cancer Biol Ther 4: 308-312, 2005. (Pubitemid 41351291)
10. Suresh K, Fraser G, Scheid E, Leber B, Gauldie J and Foley R: Generation of in vitro B-CLL specific HLA class I restricted CTL responses using autologous dendritic cells pulsed with necrotic tumor lysate. Leuk Lymphoma 47: 297-306, 2006. (Pubitemid 43084570)
11. Guo G, Chen S, Zhang J, Luo L, Yu J, Dong H, Xu H, Su Z and Wu L: Antitumor activity of a fusion of esophageal carcinoma cells with dendritic cells derived from cord blood. Vaccine 23: 5225-5230, 2005. (Pubitemid 41443428)
12. Ohshita A, Yamaguchi Y, Minami K, Hihara J and Toge T: Generation of tumor-reactive effector lymphocytes using tumor RNA-introduced dendritic cells in gastric cancer patients. Int J Oncol (In press).
13. Aruga A, Yamauchi K, Takasaki K, Furukawa T and Hanyu F: Induction of autologous tumor-specific cytotoxic T cells in patients with liver cancer. Characterizations and clinical utilization. Int J Cancer 49: 19-24, 1991.
14. Soda H, Koda K, Yasutomi J, Oda K, Takiguchi N, Saito N and Nakajima N: Adoptive immunotherapy for advanced cancer patients using in vitro-activated cytotoxic T lymphocytes. J Surg Oncol 72: 211-217, 1999. (Pubitemid 30007790)
15. Schendel DJ, Frankenberger B, Jantzer P, Cayeux S, Nobetaner E, Willimsky G, Maget B, Pohla H and Blankenstein T: Expression of B7.1 (CD80) in a renal cell carcinoma line allows expansion of tumor-associated cytotoxic T lymphocytes in the presence of an alloresponse. Gene Ther 7: 2007-2014, 2000. (Pubitemid 32036766)
16. Yamaguchi Y, Ohta K, Shimizu K, Minami K, Noma K, Hihara J and Toge T: Generation of cytotoxic effector lymphocytes by MLTC using tumor cells genetically modified to secrete interleukin-2. Anticancer Res 21: 669-677, 2001. (Pubitemid 32267591)
17. Imada M and Fujimoto S: T cell response to embryonal carcinoma F9 cells: induction and characterization of T cell receptor alpha beta + double-negative cytotoxic T lymphocytes. Jpn J Cancer Res 84: 58-64, 1993. (Pubitemid 23068772)
18. Sekine T, Shiraiwa H, Yamazaki T, Tobisu K and Kakizoe T: A feasible method for expansion of peripheral blood lymphocytes by culture with immobilized anti-CD3 monoclonal antibody and interleukin-2 for use in adoptive immunotherapy of cancer patients. Biomed Pharmacother 47: 73-78, 1993. (Pubitemid 23179962)
19. Miyahara E, Yamaguchi Y, Minami K, Hihara J, Noma K, Toge T, Takafuta T and Fujimura K: T-cell receptor Vβ gene usage of human cytotoxic T-cell clones obtained from gastric cancer patients. Anticancer Res 19: 2057-2066, 1999. (Pubitemid 29392770)
20. Ohta K, Yamaguchi Y, Shimizu K, Miyahara E and Toge T: Novel system for generation cytotoxic effector lymphocytes using carcinoembryonic antigen (CEA) peptide and cultured dendritic cells. Anticancer Res 22: 2597-2606, 2002. (Pubitemid 36069286)
21. Huang LQ, Brasseur F, Serrano A, De Plaen E, Boon T, Van der Bruggen P and Van Pel A: Cytolytic T lymphocytes recognize an antigen encoded by MAGE-A10 on a human melanoma. J Immunol 162: 6849-6854, 1999. (Pubitemid 29309414)
22. Kawakami Y, Dang N, Wang X, Tupesis J, Robbins PF, Wang RF, Wunderlich JR, Yannelli JR and Rosenberg SA: Recognition of shared melanoma antigens in association with major HLA-A alleles by tumor infiltrating T lymphocytes from 123 patients with melanoma. J Immunother 23: 17-27, 2000. (Pubitemid 30079822)
23. Chiari R, Hames G, Stroobant V, Texier C, Maillere B, Boon T and Coulie PG: Identification of a tumor-specific shared antigen derived from an Eph receptor and presented to CD4 T cells on HLA class II molecules. Cancer Res 60: 4855-4863, 2000.
24. Takenoyama M, Yoshino I, Eifuku R, So T, Imahayashi S, Sugaya M, Yasuda M, Inoue M, Ichiyoshi Y, Osaki T, Nagashima A, Nomoto K and Yasumoto K: Successful induction of tumor-specific cytotoxic T lymphocytes from patients with non-small cell lung cancer using CD80-transfected autologous tumor cells. Jpn J Cancer Res 92: 309-315, 2001. (Pubitemid 32288293)
25. Alters SE, Gadea JR, Sorich M, O'Donoghue G, Talib S and Philip R: Dendritic cells pulsed with CEA peptide induce CEA-specific CTL with restricted TCR repertoire. J Immunother 21: 17-26, 1998. (Pubitemid 28044832)
26. Xue S, Gillmore R, Downs A, Tsallios A, Holler A, Gao L, Wong V, Morris E and Stauss HJ: Exploiting T cell receptor genes for cancer immunotherapy. Clin Exp Immunol 139: 167-172, 2005. (Pubitemid 40222832)